You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The investment bank believes there's more risk for a downside on the company's stock than there is potential for an upside.
The investment bank said the company's stock has performed well in recent years and is now "appropriately priced."
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
GenMark officials announced an expected delay in launching the CE-marked version of the ePlex system, which in turn affected its US launch timeline.
The investment bank issued its downgrade citing concerns about changes to Cepheid's sales force and a flattening of its MRSA assay sales.
In addition to a steep slide in the company's share price, Raymond James lowered its rating for Cepheid's stock to Market Perform.
BTIG and Mizuho downgraded Illumina's stock after it preannounced third quarter revenue estimates that fell short of analysts' average expectations.
The investment bank also cited challenges for Illumina in penetrating the clinical diagnostics markets and driving physician adoption of its tests.
The investment bank downgraded Illumina to a Neutral rating after the company missed the consensus Wall Street estimate for its revenues.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.